Addendum
Risankizumab (Crohn disease) – Addendum to Commission A22-133
Report documents
-
Addendum
Risankizumab (Crohn disease) – Addendum to Commission A22-133
Dossier assessment
Indication:
Adults with moderately to severely active Crohn’s disease
Result of dossier assessment:
- who have had an inadequate response to, lost response to, or were intolerant to conventional therapy: added benefit not proven
- who have had an inadequate response to, lost response to, or were intolerant to a biologic therapy (TNF-alpha antagonist or integrin inhibitor or interleukin inhibitor): after addendum now hint of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2023-06-15 A G-BA decision was published.
Project details
- Project no.
- A23-40
- Commission
- Commission awarded on 03.05.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V
Status: Commission completed